Anchor Investment Management LLC Has $543,000 Position in Hologic, Inc. (NASDAQ:HOLX)

Anchor Investment Management LLC lessened its position in Hologic, Inc. (NASDAQ:HOLX) by 5.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 7,530 shares of the medical equipment provider’s stock after selling 400 shares during the quarter. Anchor Investment Management LLC’s holdings in Hologic were worth $543,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of HOLX. Brooklyn Investment Group raised its holdings in shares of Hologic by 14.7% in the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 145 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 159 shares in the last quarter. Trivant Custom Portfolio Group LLC lifted its position in Hologic by 2.1% during the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock worth $602,000 after buying an additional 169 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Hologic by 4.1% in the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider’s stock valued at $343,000 after acquiring an additional 188 shares in the last quarter. Finally, Capital Investment Counsel Inc raised its holdings in Hologic by 3.6% during the fourth quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider’s stock worth $413,000 after acquiring an additional 200 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

HOLX has been the topic of several recent analyst reports. Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target on the stock. in a research report on Monday, February 3rd. Royal Bank of Canada lowered their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. Raymond James reiterated an “outperform” rating and issued a $90.00 target price (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Finally, Morgan Stanley dropped their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Hologic presently has a consensus rating of “Hold” and a consensus price target of $84.62.

Hologic Price Performance

NASDAQ:HOLX opened at $57.86 on Wednesday. Hologic, Inc. has a 52 week low of $56.27 and a 52 week high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The firm’s 50-day simple moving average is $62.04 and its 200 day simple moving average is $71.25. The firm has a market cap of $12.98 billion, a price-to-earnings ratio of 18.25, a P/E/G ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, sell-side analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.